Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection

被引:256
|
作者
Sugimura, Hiroshi
Nichols, Francis C.
Yang, Ping
Allen, Mark S.
Cassivi, Stephen D.
Deschamps, Claude
Williams, Brent A.
Pairolero, Peter C.
机构
[1] Mayo Clin, Div Gen Thorac Surg, Coll Med, Dept Hlth Sci Res, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Biostat Sect, Rochester, MN 55905 USA
来源
ANNALS OF THORACIC SURGERY | 2007年 / 83卷 / 02期
关键词
D O I
10.1016/j.athoracsur.2006.08.046
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Survival characteristics of patients who have recurrent nonsmall-cell lung cancer after surgical resection are not well understood. Little objective evidence exists to justify treatment for these patients. Methods. We prospectively followed 1,361 consecutive patients with nonsmall-cell lung cancer who underwent complete surgical resection at our institution from January 1997 to December 2001. Only patients having recurrent cancer were included in the analysis. Multivariable Cox proportional hazards models were used to evaluate the effect of prognostic factors on postrecurrence survival. Results. Follow-up was achieved in 1,073 patients, and recurrent cancer developed in 445. Complete information was available on 390 patients for analysis. There were 262 men and 128 women. Median age at time of recurrence was 69 years. Median time from surgical resection to recurrence was 11.5 months, and median postrecurrence survival was 8.1 months. Recurrence was intrathoracic in both in 47. Treatments after recurrence included surgery in 43 patients, chemotherapy in 59, radiation in 73, and a combination in 96. All patients who received treatment survived longer than those who received no treatment. Preoperative chemotherapy and postoperative radiotherapy for the primary lung cancer, poor Eastern Cooperative Oncology Group Performance Status, decreased disease-free interval from initial resection to recurrence, symptoms at recurrence, and certain location of recurrence significantly decreased postrecurrence survival. Conclusions. In our experience, treatment for recurrent nonsmall-cell lung cancer significantly prolongs survival. Various treatment modalities including surgery should be considered in patients with postoperative recurrent nonsmall-cell lung cancer. (c) 2007 by The Society of Thoracic Surgeons.
引用
收藏
页码:409 / 418
页数:10
相关论文
共 50 条
  • [21] Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma
    Stojsic, Jelena
    Stankovic, Tijana
    Stojkovic, Sonja
    Milinkovic, Vedrana
    Dinic, Jelena
    Milosevic, Zorica
    Milovanovic, Zorka
    Tanic, Nikola
    Bankovic, Jasna
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2015, 98 (01) : 27 - 32
  • [22] Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients
    Williams, BA
    Sugimura, H
    Endo, C
    Nichols, FC
    Cassivi, SD
    Allen, MS
    Pairolero, PC
    Deschamps, C
    Yang, P
    ANNALS OF THORACIC SURGERY, 2006, 81 (03): : 1021 - 1027
  • [24] Association between duration of immunotherapy and overall survival in advanced nonsmall-cell lung cancer
    Sun, Lova
    Bleiberg, Benjamin Aaron
    Hwang, Wei-Ting
    Marmarelis, Melina Elpi
    Langer, Corey J.
    Singh, Aditi Puri
    Cohen, Roger B.
    Mamtani, Ronac
    Aggarwal, Charu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Uptake of Adjuvant Durvalumab After Definitive Concurrent Chemoradiotherapy for Stage III Nonsmall-cell Lung Cancer
    Bryant, Alex K.
    Yin, Huiying
    Schipper, Matthew J.
    Paximadis, Peter A.
    Boike, Thomas P.
    Bergsma, Derek P.
    Movsas, Benjamin
    Dess, Robert T.
    Mietzel, Melissa A.
    Kendrick, Randi
    Seferi, Merita
    Dominello, Michael M.
    Matuszak, Martha M.
    Jagsi, Reshma
    Hayman, James A.
    Pierce, Lori J.
    Jolly, Shruti
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2022, 45 (04): : 142 - 145
  • [26] Local failure patterns after radical resection and adjuvant chemotherapy in patients with pN2 nonsmall-cell lung cancer: A retrospective analysis
    Wang, Chenyu
    Li, Haixia
    Chen, Yongshun
    Ge, Hong
    INDIAN JOURNAL OF CANCER, 2020, 57 (03) : 323 - 329
  • [27] Preoperative chemotherapy does not increase complications after nonsmall cell lung cancer resection
    Perrot, E
    Guibert, B
    Mulsant, P
    Blandin, S
    Arnaud, I
    Roy, P
    Geriniere, L
    Souquet, PJ
    ANNALS OF THORACIC SURGERY, 2005, 80 (02): : 423 - 427
  • [28] Immune Response After Radiofrequency Ablation and Surgical Resection in Nonsmall Cell Lung Cancer
    Schneider, Thomas
    Hoffmann, Hans
    Dienemann, Hendrik
    Herpel, Ester
    Heussel, Claus Peter
    Enk, Alexander H.
    Ring, Sabine
    Mahnke, Karsten
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2016, 28 (02) : 585 - 592
  • [29] LOCALLY RECURRENT NON-SMALL-CELL LUNG-CANCER AFTER COMPLETE SURGICAL RESECTION
    SHAW, EG
    BRINDLE, JS
    CREAGAN, ET
    FOOTE, RL
    TRASTEK, VF
    BUSKIRK, SJ
    MAYO CLINIC PROCEEDINGS, 1992, 67 (12) : 1129 - 1133
  • [30] A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer
    Yin Wu
    Dhruva Biswas
    Ieva Usaite
    Mihaela Angelova
    Stefan Boeing
    Takahiro Karasaki
    Selvaraju Veeriah
    Justyna Czyzewska-Khan
    Cienne Morton
    Magdalene Joseph
    Sonya Hessey
    James Reading
    Andrew Georgiou
    Maise Al-Bakir
    Nicholas McGranahan
    Mariam Jamal-Hanjani
    Allan Hackshaw
    Sergio A. Quezada
    Adrian C. Hayday
    Charles Swanton
    Nature Cancer, 2022, 3 : 696 - 709